Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
NMRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $17.19
Previous CloseN/A
Volume2.95M
Average Volume (3M)1.48M
Market Cap
$183.04M
Enterprise Value$1.77B
Total Cash (Recent Filing)$142.15M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
May 13, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding161,978,930
10 Day Avg. Volume1,378,905
30 Day Avg. Volume1,476,597
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap9.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.73
Forecast
1Y Price Target
$6.67Price Target Upside490.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Market PositionNeumora is back in the pole position to be first to market with a KORA in MDD due to aticaprant's development being on hold.
Pipeline ProgressOptimism remains for NMRA's broader pipeline, with new candidates like the M4 PAM for schizophrenia expected to advance to clinical trials.
Strategic AdjustmentsNeumora recently announced plans to amend its ongoing KOASTAL-2 and -3 studies, adding additional stringency to site and patient selection to attempt to maximize the probability of success for the studies.
Bears Say
Drug Efficacy ConcernsThe failure of the KOASTAL-1 trial raises concerns about the efficacy potential of NMRA's class of drugs.
Investor ConfidenceThe discontinuation of Johnson & Johnson's aticaprant might hurt investor confidence in the near-term.
Market SkepticismInvestor skepticism may increase towards the KORA mechanism of action and other neuropsychiatry drug candidates due to the recent news.
---
Ownership Overview
25.46% Insiders
10.47% Mutual Funds
33.10% Other Institutional Investors
25.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $1.11 and its highest was $17.19 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $183.04M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Mar 03, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.424 by $0.054.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 161,978,930 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.424. Following the earnings report the stock price went down -10.256%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
---
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.67 (490.27% Upside)
$6.67 (490.27% Upside)
Blogger Sentiment
Neutral
NMRA Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 116.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.91%
12-Months-Change
Fundamentals
Return on Equity
-64.48%
Trailing 12-Months
Asset Growth
-36.12%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. (NMRA) is a biotechnology company focused on developing precision medicines for neuropsychiatric and neurodegenerative disorders. The company leverages data-driven insights and neuroscience expertise to address the underlying biological pathways of brain diseases. Neumora's pipeline includes multiple investigational therapies targeting various neurological conditions, with a commitment to improving patient outcomes through innovative drug development.
---
NMRA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company in transition, with strong financials and leadership changes poised to drive future growth. However, setbacks in the KOASTAL-1 study and the discontinuation of bipolar depression trials pose significant challenges. The overall sentiment is balanced between optimism for future potential and caution due to current setbacks.Read More>---
NMRA Stock 12 Month Forecast
Average Price Target
$6.67
▲(490.27% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Vertex Pharmaceuticals
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering NMRA
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-61.30%
reiterated a buy rating 18 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -61.30% per trade.
---